Over time
China over time. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.
Innovative drug approvals
China, 2024 to 2025
Every record
5 records · 1 region · 2024–2025. Each period links to its record: the value, its source evidence and original document.
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: MOFCOM, NHSA, State Council. Licence: CC BY 4.0.
Embed this chart
For automatic sizing and multiple charts, see the JavaScript embed guide.
Free to embed anywhere, including commercially. The attribution bar is part of the chart. The link under the frame is optional: keep it, remove it or mark it rel="nofollow".
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (MOFCOM, NHSA, State Council); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Total number of innovative pharmaceutical products granted regulatory marketing authorization.
- Measure
- One slice of Drug approvals ( form: count, segment: innovative ) . Total number of therapeutic drugs granted regulatory marketing approval. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 3 documents
| Document | Publisher | Published | Data points |
|---|---|---|---|
| 2025年我国批准创新药76个 对外授权超千亿美元 | MOFCOM | — | 2 |
| 创新高！去年我国批准创新药76个 对外授权破千亿美元 | NHSA | — | 2 |
| 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网 | State Council | — | 1 |
Other slices of drug approvals
- First-in-class drug approvals 9 first in class
- New active substance approvals 6 new active substance
- Novel drug approvals 3 novel
- Pediatric medicine approvals 3 pediatric
- Rare disease medicine approvals 3 rare disease
- Approved innovative drugs designated as breakthrough therapies 2 breakthrough therapy
- Common new active substance approvals across major regulatory authorities (multi-year total) 2 cumulative · common across authorities · new active substance
- Domestic first-in-class drug approvals 2 domestic · first in class
- Domestic innovative biological product approvals 2 domestic · innovative biologic
- Domestic innovative chemical drug approvals 2 domestic · innovative chemical
- Domestic innovative drug approvals (half year) 2 domestic · innovative
- Domestic share of approved innovative biological products 2 domestic · innovative biologic
Frequently asked questions
What is the latest innovative drug approvals?
China: 76 in 2025, +58.3% on 2024.
Where does this data come from?
From 3 documents published by MOFCOM, NHSA, State Council. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Innovative drug approvals [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/innovative-drug-approvals
"Innovative drug approvals." StatOrigin, 2026, https://statorigin.org/indicators/innovative-drug-approvals. Accessed 28 Oct. 2026.
StatOrigin. "Innovative drug approvals." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/innovative-drug-approvals.
@misc{statorigin_innovative_drug_approvals_2026, title = {Innovative drug approvals}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/innovative-drug-approvals}, note = {Data set. Accessed 2026-10-28} }